Generic QuilliChew ER Availability
Last updated on Apr 10, 2025.
See also: Generic Quillivant XR
QuilliChew ER is a brand name of methylphenidate, approved by the FDA in the following formulation(s):
QUILLICHEW ER (methylphenidate hydrochloride - tablet, extended release, chewable;oral)
-
Manufacturer: NEXTWAVE PHARMS
Approval date: December 4, 2015
Strength(s): 20MG [RLD], 30MG [RLD], 40MG [RLD]
Is there a generic version of QuilliChew ER available?
No. There is currently no therapeutically equivalent version of QuilliChew ER available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of QuilliChew ER. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Methylphenidate extended release chewable tablet
Patent 10,857,143
Issued: December 8, 2020
Inventor(s): Tu Yu-Hsing & Perumal Ashok & Kathala Kalyan
Assignee(s): TRIS PHARMA, INCAn oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.
Patent expiration dates:
- August 14, 2033✓✓
- August 14, 2033
-
Methylphenidate extended release chewable tablet
Patent 11,103,494
Issued: August 31, 2021
Inventor(s): Tu Yu-Hsing & Perumal Ashok & Kathala Kalyan
Assignee(s): TRIS PHARMA, INCAn oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.
Patent expiration dates:
- August 14, 2033✓
- August 14, 2033
-
Methylphenidate extended release chewable tablet
Patent 11,103,495
Issued: August 31, 2021
Inventor(s): Tu Yu-Hsing & Perumal Ashok & Kathala Kalyan
Assignee(s): TRIS PHARMA, INCAn oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate—ion exchange resin complex, a barrier coated methylphenidate—ion exchange resin complex—matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.
Patent expiration dates:
- August 14, 2033✓✓
- August 14, 2033
-
Methylphenidate extended release chewable tablet
Patent 11,633,389
Issued: April 25, 2023
Inventor(s): Tu; Yu-Hsing et al.
Assignee(s): TRIS PHARMA, INC (Monmouth Junction, NJ)An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.
Patent expiration dates:
- August 14, 2033✓
- August 14, 2033
-
Modified release formulations containing drug-ion exchange resin complexes
Patent 8,202,537
Issued: June 19, 2012
Inventor(s): Mehta Ketan & Tu Yu-Hsing
Assignee(s): Tris Pharma IncA solid dose composition containing a mixture of a cured, modified release-barrier coated methylphenidate-ion exchange resin complex-matrix and an uncoated methylphenidate-ion exchange resin complex is described. The barrier coated methylphenidate-ion exchange resin complex-matrix comprises methylphenidate complexed with a pharmaceutically acceptable ion-exchange resin to form the complex which is admixed with a polymer to form a methylphenidate-ion exchange resin complex-matrix, which is subsequently coated with a modified release coating. The modified coating contains polyvinyl acetate polymer and a plasticizer and is cured.
Patent expiration dates:
- March 15, 2027✓
- March 15, 2027
-
Orally effective methylphenidate extended release powder and aqueous suspension product
Patent 8,287,903
Issued: October 16, 2012
Inventor(s): Mehta Ketan & Tu Yu-Hsing & Perumal Ashok
Assignee(s): Tris Pharma IncAn oral methylphenidate powder which is reconstitutable into a final oral aqueous sustained release formulation containing at least about 50%, or at least about 80% by weight water based on the total weight of the suspension, is provided. The powder is a blend containing a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and a water soluble buffering agent such that upon formed into an aqueous liquid formulation, the formulation has a pH in the range of about 3.5 to about 5, or about 4 to about 4.5. Following administration of a single dose of the oral aqueous methylphenidate suspension, a therapeutically effective amount of methylphenidate is reached in less than one hour and the composition provides a twelve-hour extended release profile.
Patent expiration dates:
- February 15, 2031✓
- February 15, 2031
-
Methylphenidate extended release chewable tablet
Patent 8,999,386
Issued: April 7, 2015
Inventor(s): Tu Yu-Hsing & Perumal Ashok & Kathala Kalyan
Assignee(s): TRIS Pharma, Inc.An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.
Patent expiration dates:
- August 14, 2033✓
- August 14, 2033
-
Methylphenidate extended release chewable tablet
Patent 9,295,642
Issued: March 29, 2016
Inventor(s): Tu Yu-Hsing & Perumal Ashok & Kathala Kalyan
Assignee(s): Tris Pharma, Inc.An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.
Patent expiration dates:
- August 14, 2033✓✓
- August 14, 2033
-
Methylphenidate extended release chewable tablet
Patent 9,545,399
Issued: January 17, 2017
Inventor(s): Tu Yu-Hsing & Perumal Ashok & Kathala Kalyan
Assignee(s): TRIS PHARMA, INC.An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.
Patent expiration dates:
- August 14, 2033✓✓
- August 14, 2033
-
Methylphenidate extended release chewable tablet
Patent 9,844,544
Issued: December 19, 2017
Inventor(s): Tu Yu-Hsing & Perumal Ashok & Kathala Kalyan
Assignee(s): TRIS PHARMA, INCAn oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.
Patent expiration dates:
- August 14, 2033✓✓
- August 14, 2033
More about QuilliChew ER (methylphenidate)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (2)
- Drug images
- Latest FDA alerts (4)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: CNS stimulants
- Breastfeeding
- En español
Patient resources
Other brands
Concerta, Ritalin, Jornay PM, Ritalin LA, ... +9 more
Professional resources
Other brands
Concerta, Ritalin, Jornay PM, Ritalin LA, ... +9 more
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.